5:23 PM
 | 
May 02, 2013
 |  BC Extra  |  Clinical News

Gilead reports more HCV data, 1Q13 earnings

Gilead Sciences Inc. (NASDAQ:GILD) reported interim data from the Phase II LONESTAR trial evaluating a once-daily, oral fixed-dose combination of sofosbuvir plus ledipasvir ( GS-5885) to treat chronic HCV genotype 1 infection. In non-cirrhotic, treatment-naïve patients, sofosbuvir plus ledipasvir for eight weeks led to a sustained virologic response (SVR) eight weeks after the end of treatment in 95% of patients, and sofosbuvir plus ledipasvir for eight weeks with...

Read the full 326 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >